An up date on Theralase now beginning the phase 1b clinical trial
The President and CEO of Theralase joins us to discuss the outlook for 2017 in terms of the cancer and therapeutic divisions. The Company is starting to enroll its first patients for the clinical trial. This is a huge step for Theralase that will first test the safety and tolerability of the treatment.
We also discuss the sales of the therapeutic division and the TLC-2000 laser. Sales were steadily increasing throughout the year. Roger shares the revenue strategy that is slightly different this year. It is shaping up to be a big year for Theralase and Roger’s team.
Click here to visit the Theralase website for more information on the two divisions.
Click download link to listen on this device: Download Show
Good advice in my opinion:
http://wallstreetonparade.com/
A safe community Bank is safer than a big commercial bank.
Thanks for the update. Finally theralase will show the World what this technology can do. Vey excited. The waiting is what buggers most people, I guess. But time is what it will need. Once the first patient is done, I can imaginethere will be plenty of Eyes on Theralase going forward. Hopefully, we can get to Nasdaq sooner rather than later. Very happy for every update you do with Theralase!
January 17, 2017 08:30 ET
Envision Solar’s EV ARC™ Transportable Solar Powered EV Charger Featured at Chevrolet Bolt Launch Promotion in San Francisco Bay Area
SAN DIEGO, CA–(Marketwired – January 17, 2017) – Envision Solar International, Inc., (OTCQB: EVSI) (“Envision Solar,” or the “Company”), the leading renewable energy, outdoor advertising, EV charging and energy security product company, announced today that its EV ARC™ product will be featured during a promotional event for the new Chevrolet Bolt in Dublin, Calif. on Jan. 18, 2017.